Skip to content

Study · Systematic review · 2017

2 results

The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies.

Baptista A, Teixeira I, Romano S, Carneiro AV, Perelman J

The European journal of health economics : HEPAC : health economics in prevention and care17 Oct 2016Cited by 11 (Europe PMC)

PMID27752788 (opens in a new tab)DOI10.1007/s10198-016-0837-7 (opens in a new tab)PepBankPUB-27752788
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewOther

    In cost-effectiveness studies in type 2 diabetes, liraglutide 1.2 mg had an ICER of up to 22,724 EUR/QALY compared with sitagliptin.

    In plain wordsIn cost studies in type 2 diabetes, liraglutide 1.2 mg cost up to 22,724 EUR per quality-adjusted life year gained compared with sitagliptin.

    Peptide
    Liraglutide
    Outcome
    Not applicableCost-effectiveness ICER, liraglutide 1.2 mg versus sitagliptin
    Study

    n: not reported in source

    Comparator
    Sitagliptin
    Outcome group
    Cost-effectiveness · Whole body
    Studied dose
    1.2 mgAs given in this study (human).

    Measurements

    ICER, up to
    22,724 EUR/QALY
    liraglutide 1.2 mg vs sitagliptin

    Source sentences

    Summary
    When compared with sitagliptin, liraglutide (GLP-1 receptor agonist) had an ICER of up to 22,724 €/QALY for the 1.2-mg dosage, and up to 32,869 €/QALY for the 1.8-mg dosage.
    1 context sentence
    Summary · context
    A total of 295 studies were identified, of which 20 were included.
  2. 02HumanSystematic reviewOther

    In cost-effectiveness studies in type 2 diabetes, liraglutide 1.8 mg had an ICER of up to 32,869 EUR/QALY compared with sitagliptin.

    In plain wordsIn cost studies in type 2 diabetes, liraglutide 1.8 mg cost up to 32,869 EUR per quality-adjusted life year gained compared with sitagliptin.

    Peptide
    Liraglutide
    Outcome
    Not applicableCost-effectiveness ICER, liraglutide 1.8 mg versus sitagliptin
    Study

    n: not reported in source

    Comparator
    Sitagliptin
    Outcome group
    Cost-effectiveness · Whole body
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    ICER, up to
    32,869 EUR/QALY
    liraglutide 1.8 mg vs sitagliptin

    Source sentences

    Summary
    When compared with sitagliptin, liraglutide (GLP-1 receptor agonist) had an ICER of up to 22,724 €/QALY for the 1.2-mg dosage, and up to 32,869 €/QALY for the 1.8-mg dosage
    1 context sentence
    Summary · context
    A total of 295 studies were identified, of which 20 were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.